Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy

Prostate Cancer and Prostatic Diseases

Volumn 12, Issue 2, 2009, Pages 116-123

  Van Poppel, H ^a   Joniau, S ^a   Van Cleynenbreugel, B ^a   Mottaghy, F M ^a   Oyen, R ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; DOCETAXEL; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIPTORELIN;

ABDOMINAL OBESITY; ADJUVANT THERAPY; ANDROGEN DEPRIVATION THERAPY; ANEMIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SCINTISCANNING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DOPPLER ECHOGRAPHY; DOSAGE SCHEDULE COMPARISON; DRUG INTERMITTENT THERAPY; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; HAIR LOSS; HOT FLUSH; HUMAN; INSULIN RESISTANCE; INTERMETHOD COMPARISON; LIBIDO DISORDER; LIVER FAILURE; LOW DRUG DOSE; METABOLIC SYNDROME X; MOOD DISORDER; MUSCLE ATROPHY; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENT CANCER; REVIEW; SIDE EFFECT; SURVIVAL TIME; TESTOSTERONE BLOOD LEVEL; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR FLARE; WEAKNESS; WEIGHT GAIN;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 67349286476     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2009.3     Document Type: Review

References (54)

1. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-1788.
2. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G et al Immediate versus deferred androgen deprivation treatment in patients with node positive prostate cancer after radical prostatectomy and pelvic lymhadenectomy. Lancet Oncol 2006; 7: 472-479.
3. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point? J Urol 2001; 165: 1146-1151.
4. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003; 61: 365-369.
5. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007; 177: 540-545.
6. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP et al EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80.
7. Khan MA, Partin AW. Management of patients with an increasing prostate-specific antigen after radical prostatectomy. Curr Urol Rep 2004; 5: 179-187.
8. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-1597.
9. Bianco Jr FJ, Scardino PT, Eastham JA. Radical prostatectomy: Long-term cancer control and recovery of sexual and urinary function ('trifecta'). Urology 2005; 66 (5 Suppl): 83-94.
10. Yossepowitch O, Eggener SE, Bianco Jr FJ, Carver BS, Serio A, Scardino PT et al. Radical prostatectomy for clinically localized, high risk prostate cancer: Critical analysis of risk assessment methods. J Urol 2007; 178: 493-499; discussion 499.
11. Dotan ZA, Bianco Jr FJ, , Rabbani F, Eastham JA, Fearn P, Scher HI et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 2005; 23: 1962-1968.
12. Deliveliotis C, Manousakas T, Chrisofos M, Skolarikos A, Delis A, Dimopoulos C. Diagnostic efficacy of transrectal ultrasound-guided biopsy of the prostatic fossa in patients with rising PSA following radical prostatectomy. World J Urol 2007; 25: 309-313.
13. Tamsel S, Killi R, Apaydin E, Hekimgil M, Demirpolat G. The potential value of power Doppler ultrasound imaging compared with grey-scale ultrasound findings in the diagnosis of local recurrence after radical prostatectomy. Clin Radiol 2006; 61: 325-330; discussion 323-324.
14. Naya Y, Okihara K, Evans RB, Babaian RJ. Efficacy of prostatic fossa biopsy in detecting local recurrence after radical prostatectomy. Urology 2005; 66: 350-355.
15. Sciarra A, Panebianco V, Salciccia S, Osimani M, Lisi S, Ciccariello M et al. Role of dynamic contrast-enhanced magnetic resonance (MR-) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 2008; 54: 589-600.
16. Barentsz J, Fütterer J, Takahashi S. Use of ultrasmall super-paramagnetic iron oxide in lymph node MR imaging in prostate cancer patients. Eur J Radiol 2007; 63: 369-372.
17. Casciani E, Polettini E, Carmenini E, Floriani I, Masselli G, Bertini L et al. Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol 2008; 190: 1187-1192.
18. Pucar D, Sella T, Schoder H. The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. Curr Opin Urol 2008; 18: 87-97.
19. Reske SN, Blumstein NM, Glatting G. [(11)C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008; 35: 9-17.
20. Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 2007; 100: 786-793.
21. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C et al. The detection rate of [(11)C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35: 18-23.
22. Schilling D, Schlemmer HP, Wagner PH, Bottcher P, Merseburger AS, Aschoff P et al. Histological verification of (11)C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int 2008.
23. Kotzerke J, Volkmer BG, Glatting G, van den Hoff J, Gschwend JE, Messer P et al. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003; 42: 25-30.
24. Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M et al Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007; 52: 423-429.
25. Raj GV, Partin AW, Polascik TJ. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 2002; 94 987-996.
26. Sodee DB, Sodee AE, Bakale G. Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med 2007; 37: 17-28.
27. Heidenreich A, Aus G, Abbou CC, Bolla M, Schmid HP, van Poppel H et al. European Association of Urology. EAU guidelines on prostate cancer. 2007; Available from www.uroweb. org/nc/professional-resources/ guidelines/online.
28. Alibhai SM, Gogov S, Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: A systematic literature review. Crit Rev Oncol Hematol 2006; 60 201-215.
29. Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol 2006; 176: 520-525.
30. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-4456.
31. Mottet N, Prayer-Galetti T, Hammerer P, Kattan MW, Tunn U. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int 2006; 98: 20-27.
32. Gillatt D. Antiandrogen treatments in locally advanced prostate cancer: are they all the same? J Cancer Res Clin Oncol 2006; 132 (Suppl 1): S17-S26.
33. Tunn U. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: Putting IAD under the spotlight. BJU Int 2007; 99 (Suppl 1): 19-22; discussion 23-14.
34. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: Initials results of the Medical Research Council Trial. Br J Urol 1997; 79: 235-246.
35. Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006; 24: 1868-1876.
36. Wirth MP, Weissbach L, Marx FJ, Heckl W, Jellinghaus W, Riedmiller H et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 2004; 45: 267-270; discussion 270.
37. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP. Bicalutamide 150mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97: 247-254.
38. Zincke H, Lau W, Bergstralh E, Blute ML. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol 2001; 166: 2208-2215.
39. Seay TM, Blute ML, Zincke H. Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol 1998; 159: 357-364.
40. Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 2001; 91: 66-73.
41. Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 2007; 178 (3 Part 1): 864-870; discussion 870-861.
42. Spiess PE, Lee AK, Busby JE, Jordan JJ, Hernandez M, Burt K et al. Surgically managed lymph node-positive prostate cancer: Does delaying hormonal therapy worsen the outcome? BJU Int 2007; 99: 321-325.
43. Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K. Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol 2009; 27: 100-105.
44. Parker C, Clarke N, Logue J, Payne H, Catton C, Kynaston H et al. RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery). Clin Oncol (R Coll Radiol) 2007; 19: 167-171.
45. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004; 171: 1141-1147.
46. Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: A matched cohort study. J Urol 2008; 179: 1830-1837; discussion 1837.
47. Makarov DV, Humphreys EB, Mangold LA, Carducci MA, Partin AW, Eisenberger MA et al. The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. J Urol 2008; 179: 156-161; discussion 161-152.
48. Moul JW. Treatment of PSA only recurrence of prostate cancer after prior local therapy. Curr Pharm Des 2006; 12: 785-798.
49. Conti PD, Atallah AN, Arruda H, Soares BG, El Dib RP, Wilt TJ. Intermittent versus continuous androgen suppression for prostatic cancer. Cochrane Database Syst Rev 2007; 4: CD005009.
50. Barqawi AB, Moul JW, Ziada A, Handel L, Crawford ED. Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. Urology 2003; 62: 872-876.
51. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004; 291: 1325-1332.
52. Stephenson AJ. Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2006; 24, (No 18S (June 20 Supplement)) 4514.
53. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008; 299: 2760-2769.
54. Pearce A, Choo R, Danjoux C, Morton G, Loblaw DA, Szumacher E et al Effect of combined treatment with salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys 2006; 65: 78-83.